Cargando…
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
INTRODUCTION: Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI). Their e...
Autores principales: | Germain, Michael J., Paul, Subir K., Fadda, George, Broumand, Varshasb, Nguyen, Andy, McGarvey, November H., Gitlin, Matthew D., Bishop, Charles W., Csomor, Philipp, Strugnell, Stephen, Ashfaq, Akhtar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650892/ https://www.ncbi.nlm.nih.gov/pubmed/36368937 http://dx.doi.org/10.1186/s12882-022-02993-3 |
Ejemplares similares
-
Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022) -
LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity
por: Strugnell, Stephen A, et al.
Publicado: (2022) -
Factors in nephrologists’ decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment
por: Reddy, Anand C., et al.
Publicado: (2023) -
Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease
por: Strugnell, Stephen A., et al.
Publicado: (2023) -
LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022)